Telmisartan Versus Valsartan in Patients With Hypertension: Effects on Cardiovascular, Metabolic, and Inflammatory Parameters.
10.4070/kcj.2011.41.10.583
- Author:
Sung Yoon LIM
1
;
Sun Won KIM
;
Eung Ju KIM
;
Jun Hyuk KANG
;
Su A KIM
;
Yun Kyung KIM
;
Jin Oh NA
;
Cheol Ung CHOI
;
Hong Euy LIM
;
Seong Woo HAN
;
Seung Woon RHA
;
Chang Gyu PARK
;
Hong Seog SEO
;
Dong Joo OH
Author Information
1. Division of Cardiology, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea. withnoel@empal.com
- Publication Type:Original Article ; Randomized Controlled Trial
- Keywords:
Hypertension;
Valsartan
- MeSH:
Benzimidazoles;
Benzoates;
Blood Pressure;
Humans;
Hypertension;
Pulse Wave Analysis;
Tetrazoles;
Valine;
Valsartan
- From:Korean Circulation Journal
2011;41(10):583-589
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND AND OBJECTIVES: Angiotensin-receptor blockers (ARBs) have beneficial effects on cardiovascular, metabolic, and inflammatory parameters in addition to controlling blood pressure (BP). However, few comparative clinical studies have been conducted with different ARBs. We compared these effects in patients with uncomplicated hypertension who were receiving telmisartan or valsartan. SUBJECTS AND METHODS: The subjects were patients with essential hypertension (48.4+/-9.6 years) who were randomly assigned to take either telmisartan (80 mg/day, n=30) or valsartan (160 mg/day, n=30) for 12 weeks. Their anthropometric, laboratory, vascular, and echocardiographic data were measured at baseline and at the end of the study. RESULTS: Baseline characteristics were not significantly different between the two groups, except for the carotid-femoral pulse wave velocity (cfPWV; telmisartan group vs. valsartan group; 841.2+/-131.0 vs. 761.1+/-104.4 cm/s, p<0.05). After 12 weeks, BP had fallen to a similar extent with mean reductions in the systolic and diastolic BP of 20.7+/-18.1 and 16.3+/-13.0 mm Hg (p<0.001, respectively) for the telmisartan and 22.5+/-17.0 and 16.8+/-9.3 mm Hg (p<0.001, respectively) for the valsartan group. Although the cfPWV and left ventricular mass index (LVMI) fell significantly only with the administration of telmisartan, they were not significantly different when baseline cfPWV was considered. The differences in the cfPWV and LVMI changes from baseline between the two groups were also not significant after adjusting for baseline cfPWV. No significant changes in other vascular, metabolic, or inflammatory parameters were observed with either treatment. CONCLUSION: The effects of a 12-week treatment with the two ARBs, telmisartan and valsartan, on cardiovascular, metabolic, and inflammatory parameters were not different in patients with uncomplicated hypertension.
